Why the study?
Does ranolazine suppress atrial and ventricular fibrillation in patients with coronary artery disease and heart failure?
Does ranolazine suppress atrial and ventricular fibrillation in patients with coronary artery disease and heart failure?
Answers are grounded in this paper and cite their sources.
Ranolazine may offer dual protection against both atrial and ventricular fibrillation in patients with coronary artery disease and heart failure.
Coronary artery disease and heart failure carry concurrent risk for atrial fibrillation and life-threatening ventricular arrhythmias. We review evidence indicating that at therapeutic concentrations, ranolazine has potential for dual suppression of these arrhythmias. Mechanisms and clinical implications are discussed.
No takes yet. Share an insight, caveat, or question.
Verrier et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: